Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citrus sinensis peel extract is a botanical product derived from the peel of the sweet orange. It is currently being investigated as an adjunctive therapy for type 2 diabetes mellitus and dyslipidemia. The extract is rich in bioactive polyphenols and flavonoids, such as hesperidin and polymethoxylated flavones, which are thought to exert antidiabetic and lipid-lowering effects. Its mechanism of action involves the inhibition of carbohydrate-hydrolyzing enzymes like alpha-amylase and alpha-glucosidase, as well as the modulation of lipid metabolism through pathways such as PPAR signaling. Clinical research led by Dr. Zeemal Iqbal at Multan Medical & Dental College evaluates its efficacy when added to standard treatments like metformin and statins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citrus sinensis peel extract.